Skip to OncoLog navigation.Skip to page content.The University of Texas MD Anderson Cancer Center MD Anderson site navigation About UsLocationsEventsCareersPublicationsHow You Can HelpContact UsmyMDAnderson
OncoLog: Report to PhysiciansEspanol Espanol
Click for Patient Referral.

Home
Previous Issues
Articles by Topic
Patient Education
About OncoLog

 

 

Spacer

From OncoLog, May 2012, Vol. 57, No. 5

Photo: Dr. Alexei Protopopov
Dr. Alexei Protopopov, an associate director at the Institute for Applied Cancer Science, demonstrates a DNA sequencing machine. Technological advances have reduced the time and cost of sequencing a human genome, improving researchers’ ability to develop experimental drugs that target cancer-causing mutations.

Advances in Gene Mapping Technology May Accelerate Cancer Drug Development

By Bryan Tutt

As new technology makes DNA sequencing faster and less expensive, researchers aim to exploit these abilities to develop novel targeted cancer therapies.

“It took about 10 years to get the first human genome sequenced,” said Giulio Draetta, M.D., Ph.D., a professor in the Department of Genomic Medicine and the director of the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center. “When the Human Genome Project’s work was conducted in the 1990s, they had huge rooms with sequencers, one next to another—these machines read along the DNA sequence to be able to divine the nucleotides that emerged; these nucleotides were then assembled together.” Systems are now available that can sequence a human genome in less than a week with a single machine, and even faster machines are being developed.

Genetic information and cancer

The information obtained from DNA sequencing is affecting cancer research in three main areas, according to Dr. Draetta.

First, mutations that affect cancer cells’ sensitivity to treatment have been identified. “Some emerging treatments are based on mapping the genome to look for mutations that respond to certain drugs,” Dr. Draetta said. For example, the melanoma drug vemurafenib specifically targets the BRAF V600E mutation and is approved by the U.S. Food and Drug Administration for the treatment of melanomas with such mutations. And non–small cell lung cancers with particular mutations to EGFR are sensitive to gefitinib and erlotinib. Second, genetic information has revealed common themes in cancer cells that explain their resistance to treatment. “Most tumors inactivate certain mechanisms that induce cell death. The tumors tend to survive even if you bang them with radiation therapy or chemotherapy,” Dr. Draetta said. “We can develop all sorts of therapies, but there is resistance because tumors don’t want to die. Now, at the genome scale, we know that these mechanisms that induce cell death are the predominant mechanisms of resistance that we have to deal with.”

Finally, DNA sequencing has revealed a greater extent of heterogeneity among cancer genomes than was once thought. A recent paper in the New England Journal of Medicine (2012; 366:883-892) described different mutations found in biopsy specimens from primary tumors and different metastatic sites in the same patients. The implication of this finding is that an agent that targets a specific mutation might be effective against a patient’s primary tumor but ineffective against metastases.

“The idea had always been that a tumor originates from a single mutated cell and that as it expands every cell in the tumor is the same. The reality is that cancer cells keep mutating as they move around the body,” Dr. Draetta said. “This makes the task of curing cancer daunting, but I like to believe that knowledge is power. The countermeasure to this problem of heterogeneity is to find commonality. The more we learn about the complexity of tumors, the more we can look for common themes or a common root cause.”

A new approach to drug development

DNA sequencing technology is a contributing factor to what Dr. Draetta described as a paradigm shift in the approach to drug development. This new research paradigm seeks to bridge gaps that are not always addressed, or are not addressed quickly, by academic research centers and pharmaceutical companies working separately.

“The more we learn about the complexity of tumors, the more we can look for common themes or a common root cause.”
– Dr. Giulio Draetta

“Academic institutions have traditionally pursued research on an individual basis. A particular scientist might be interested in curing a particular disease—and once the scientist has published reports, pharmaceutical companies have developed drugs based on the research,” said Dr. Draetta, who has led research laboratories in both settings. He pointed out that the traditional approach makes it difficult for pharmaceutical companies to invest in research for therapies that target a specific mutation found in a small subset of cancer patients.

“Drugs like blood pressure medication, which many patients may take every day for 20–30 years, are profitable for pharmaceutical companies and enable them to invest in research,” Dr. Draetta said. “But the companies have realized that they are not going to make that kind of money with a single targeted oncology drug because the complexity of cancer makes it unlikely that a single drug will be used to treat a large number of patients.”

At MD Anderson’s Institute for Applied Cancer Science, research teams work to identify targets for new drugs and then develop the drugs themselves. So far, the institute has about 70 research professionals from such fields as medicinal chemistry, pharmacology, genomics, bioinformatics, biology, and biochemistry. These professionals are divided into eight teams that work simultaneously on different aspects of multiple projects.

Dr. Draetta said the ability to quickly sequence a cancer genome makes the collaboration between work groups possible. “We can immediately go back and look at gene databases and ask, ‘Is this gene really altered? Which subtype of breast cancer is it? Can we find cancer cell lines that carry this alteration?’ Then we can study those cell lines and make sure there is dependency on the mutation,” he said. Dr. Draetta explained that the fact that a gene is amplified does not mean that the cancer needs it to survive. The cancer may have needed the mutation at one point, but additional mutations can make the first mutation redundant. Genomic information helps identify such mutations as unlikely therapeutic targets before drugs are developed.

“Each team is working on a specific time line to make sure a drug candidate’s mechanism of action is valid before it goes to clinical trials,” Dr. Draetta said. “The idea is to make sure there are no obvious mechanisms of resistance to a particular agent so that we invest our energy in developing the drugs that have the most potential.” Drug candidates that are validated early can be developed and brought to preclinical and clinical trials. “If we can find even small populations of patients who will benefit from a drug, we will bring it forward. Of course, we want to help as many patients as we can, are not driven by how many vials of a drug we can sell.”

Not only do the institute’s research teams coordinate with each other, they also work closely with other researchers and clinicians at MD Anderson. For example, Dr. Draetta regularly consults physicians in the Department of Investigational Cancer Therapeutics to determine what drugs currently in clinical trials are likely to become the standard of care that might be given along with a drug he is developing for a particular type of cancer.

Dr. Draetta sees this ability to bring together all aspects of research as a unique advantage of the institute’s location at a major cancer center. “I worked in the pharmaceutical industry for many years. My teams identified many compounds and developed them on our own, but we missed the ability to go back and open a dialogue with the biologists who did the initial re search,” Dr. Draetta said. “Now, we are engaging biologists and clinicians early on.”

Genomic information can also identify which patients are most likely to benefit from a drug. “We’re seeing in clinical trials that if you match the therapy with the mutation, you get much better results,” Dr. Draetta said, adding that matching therapy to mutations also can spare patients from unnecessary treatment.

“I’m very enthusiastic about this new research model,” Dr. Draetta said. “We want to use bioinformatics—computational tools—to look at common points of attack. It’s about working together and coordinating the effort.”

For more information, contact Dr. Giulio Draetta at 713-792-6803.

Other articles in OncoLog, May 2012 issue:

TopTOP

Home/Current Issue | Previous Issues | Articles by Topic | Patient Education
About Oncolog | Contact OncoLog
| Sign Up for E-mail Alerts

©2014 The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd., Houston, TX 77030
1-877-MDA-6789 (USA) / 1-713-792-3245  
 Patient Referral    Legal Statements    Privacy Policy

Derivacíon de pacientes